CN104357394B - 一种自体外周血淋巴细胞dc‑cik的培养方法 - Google Patents
一种自体外周血淋巴细胞dc‑cik的培养方法 Download PDFInfo
- Publication number
- CN104357394B CN104357394B CN201410573897.7A CN201410573897A CN104357394B CN 104357394 B CN104357394 B CN 104357394B CN 201410573897 A CN201410573897 A CN 201410573897A CN 104357394 B CN104357394 B CN 104357394B
- Authority
- CN
- China
- Prior art keywords
- cik
- cell
- day
- cells
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 title claims abstract description 7
- 238000012136 culture method Methods 0.000 title abstract 4
- 102000004127 Cytokines Human genes 0.000 title description 3
- 108090000695 Cytokines Proteins 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 116
- 210000002966 serum Anatomy 0.000 claims abstract description 27
- 210000004405 cytokine-induced killer cell Anatomy 0.000 claims abstract description 24
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 7
- 239000011886 peripheral blood Substances 0.000 claims abstract description 7
- 108010002350 Interleukin-2 Proteins 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 238000005119 centrifugation Methods 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 239000012679 serum free medium Substances 0.000 claims description 3
- 108010078233 Thymalfasin Proteins 0.000 claims description 2
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 2
- 229960004231 thymalfasin Drugs 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract description 31
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract description 28
- 230000001665 lethal effect Effects 0.000 abstract description 6
- 210000005087 mononuclear cell Anatomy 0.000 abstract description 5
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract description 4
- 230000004913 activation Effects 0.000 abstract description 3
- 230000003321 amplification Effects 0.000 abstract description 3
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 3
- 238000003501 co-culture Methods 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 4
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 abstract 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 24
- 229940045513 CTLA4 antagonist Drugs 0.000 description 24
- 102000000588 Interleukin-2 Human genes 0.000 description 13
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 12
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 12
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 9
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 102100020870 La-related protein 6 Human genes 0.000 description 5
- 108050008265 La-related protein 6 Proteins 0.000 description 5
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 5
- 102100035793 CD83 antigen Human genes 0.000 description 4
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000013394 immunophenotyping Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 201000010174 renal carcinoma Diseases 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 102000004125 Interleukin-1alpha Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000037111 immune power Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003726 plant lectin Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
培养天数 | 第1天 | 第7天 | 第14天 | 第18天 | 第21天 |
细胞数目*108 | 0.48 | 12.1 | 60.1 | 73.5 | 112.3 |
效靶比 | CIK | DC-CIK |
10:1 | 51.23±2.08 | 65.04±2.13* |
20:1 | 63.44±3.16 | 75.18±4.15* |
40:1 | 85.24±3.38 | 93.01±3.57* |
免疫表型 | 未添加PD-1单抗、CTLA-4单抗 | 添加PD-1单抗、CTLA-4单抗 |
CD3+CD56+ | 8.5 | 34.9 |
CD3+CD8+ | 78.9 | 65.6 |
CD4+CD25+ | 11.1 | 0.9 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410573897.7A CN104357394B (zh) | 2014-10-24 | 2014-10-24 | 一种自体外周血淋巴细胞dc‑cik的培养方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410573897.7A CN104357394B (zh) | 2014-10-24 | 2014-10-24 | 一种自体外周血淋巴细胞dc‑cik的培养方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104357394A CN104357394A (zh) | 2015-02-18 |
CN104357394B true CN104357394B (zh) | 2017-03-22 |
Family
ID=52524707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410573897.7A Expired - Fee Related CN104357394B (zh) | 2014-10-24 | 2014-10-24 | 一种自体外周血淋巴细胞dc‑cik的培养方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104357394B (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105062968B (zh) * | 2015-09-14 | 2019-01-15 | 广州赛莱拉干细胞科技股份有限公司 | 一种dc-cik细胞培养试剂及其培养方法 |
CN105087488A (zh) * | 2015-09-15 | 2015-11-25 | 上海麦禾生物科技有限公司 | 一种肿瘤抗原诱导的dc-cik细胞的制备方法及应用 |
CN105254744B (zh) * | 2015-10-29 | 2019-01-01 | 中国医学科学院医药生物技术研究所 | 多肽xzz-5的异源表达及其在增强cik细胞杀瘤活性中的应用 |
CN105969727A (zh) * | 2015-12-29 | 2016-09-28 | 山东省齐鲁细胞治疗工程技术有限公司 | 一种脐血淋巴细胞dc-cik的培养方法 |
CN105734015A (zh) * | 2016-03-10 | 2016-07-06 | 广州赛莱拉干细胞科技股份有限公司 | Dc-ctl细胞的培养方法 |
CN105907712B (zh) * | 2016-04-25 | 2021-01-26 | 深圳市第二人民医院 | 抗原活化的免疫细胞及其培养方法和应用 |
CN105695406A (zh) * | 2016-04-27 | 2016-06-22 | 天津普瑞赛尔生物科技有限公司 | 制备具有高效肿瘤杀伤性dc-cik免疫细胞的方法及制得的dc-cik免疫细胞 |
CN105861433A (zh) * | 2016-04-27 | 2016-08-17 | 天津普瑞赛尔生物科技有限公司 | 制备具有高效肿瘤杀伤性cik细胞制剂的方法及制得的cik细胞制剂 |
CN106244534A (zh) * | 2016-08-15 | 2016-12-21 | 安徽省新安干细胞工程有限公司 | 一种细胞毒型混合杀伤细胞的制备方法 |
JP6993812B2 (ja) * | 2016-08-17 | 2022-01-14 | 治範 小田 | 細胞傷害活性を向上させたリンパ球の培養方法及び該方法で得られた細胞傷害活性を向上させたリンパ球を含む細胞免疫治療剤 |
CN106729705B (zh) * | 2017-01-23 | 2018-04-06 | 河南省华隆生物技术有限公司 | 一种药物组合物及其应用 |
CN106955352A (zh) * | 2017-03-27 | 2017-07-18 | 顺昊细胞生物技术(天津)股份有限公司 | 一种用于治疗癌症的药物组合物和试剂盒 |
CN107541526B (zh) * | 2017-08-23 | 2019-12-10 | 北京瑞健科技有限公司 | 能敲低内源性ctla4表达的cik及制备方法与应用 |
CN109402055A (zh) * | 2018-11-12 | 2019-03-01 | 广州航华生物医药科技有限公司 | 一种dc-cik细胞培养试剂盒及其培养方法 |
CN109825473A (zh) * | 2019-01-07 | 2019-05-31 | 山东博森医学工程技术有限公司 | 一种采用tlr7激动剂刺激的自体外周血淋巴细胞的培养方法 |
CN113046313A (zh) * | 2021-03-18 | 2021-06-29 | 重庆福美干细胞生物科技发展有限公司 | 用于高效诱导扩增人体外周血杀伤性免疫细胞的组合物、试剂盒以及该免疫细胞的培养方法 |
CN116064397A (zh) * | 2021-11-02 | 2023-05-05 | 上海细胞治疗集团有限公司 | 表达免疫检查点抑制剂的超级dc及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR062247A1 (es) * | 2005-03-08 | 2008-10-29 | Pharmacia & Upjohn Co Llc | Composiciones de anticuerpos anti-ctla-4 |
CN102526716B (zh) * | 2011-12-07 | 2013-03-27 | 蔡颖 | 一种特异性肿瘤杀伤细胞的制备 |
-
2014
- 2014-10-24 CN CN201410573897.7A patent/CN104357394B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN104357394A (zh) | 2015-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104357394B (zh) | 一种自体外周血淋巴细胞dc‑cik的培养方法 | |
CN104371974B (zh) | 一种自体外周血淋巴细胞cik的培养方法 | |
KR101133185B1 (ko) | 자연살해세포의 증식방법 | |
CN104357390B (zh) | 同时扩增cd3+cd56+cik细胞和cd3‑cd56+nk细胞的方法 | |
CN105969727A (zh) | 一种脐血淋巴细胞dc-cik的培养方法 | |
CN108251365B (zh) | 免疫细胞培养基体系 | |
CN108588022B (zh) | 体外培养富集人cd4+和cd8+ tcm细胞的方法 | |
CN102676455B (zh) | 脐带血来源的树突状细胞及树突状细胞疫苗的制备方法 | |
CN102600462A (zh) | 人树突状细胞肿瘤疫苗及其制备方法和应用 | |
CN105176927A (zh) | 一种细胞毒性增强的高效靶向杀伤nk/cik细胞的制备方法 | |
CN109825473A (zh) | 一种采用tlr7激动剂刺激的自体外周血淋巴细胞的培养方法 | |
CN107502590A (zh) | 一种人类脐带血造血干细胞高效扩增nk细胞的方法 | |
WO2015014291A1 (zh) | 通过无血清培养扩增活化淋巴细胞的方法 | |
CN105112371A (zh) | 脐带血单个核细胞来源的dc-cik细胞制取方法及制剂 | |
CN106754704B (zh) | 免疫细胞体外诱导扩增的方法 | |
CN112410294A (zh) | 一种外周血cik细胞的扩增培养方法 | |
CN105505871B (zh) | 一种有效扩增cik且提高其特异性杀瘤能力的方法 | |
CN105018427B (zh) | 一种增强ctl免疫反应的dc细胞培养方法 | |
CN105106237B (zh) | 一种高效杀伤肿瘤细胞生物制剂 | |
CN105969731B (zh) | 一种利用恶性胸腹水大量制备高杀伤活性til细胞的方法 | |
CN107574148A (zh) | 一种自然杀伤细胞(nk细胞)培养基及其制备方法 | |
CN105861433A (zh) | 制备具有高效肿瘤杀伤性cik细胞制剂的方法及制得的cik细胞制剂 | |
CN102861107A (zh) | Dc-cik细胞治疗组合物 | |
CN109402057A (zh) | 一种负载肿瘤细胞外泌体的dc-ctl细胞的培养方法 | |
CN109957543A (zh) | 利用脐带血大量扩增脐血nk细胞的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 310018 Hangzhou economic and Technological Development Zone, Zhejiang, No. 6 Avenue, No. 452 Applicant after: ADLAI NORTYE BIOPHARMA Co.,Ltd. Address before: 310018 Hangzhou economic and Technological Development Zone, Zhejiang, No. 6 Avenue, No. 452 Applicant before: HANGZHOU ADLAI NORTYE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
COR | Change of bibliographic data | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Culture method of autologous peripheral blood lymphocyte DC-CIK (Dendritic Cell- Cytokine-induced Killer) Effective date of registration: 20171228 Granted publication date: 20170322 Pledgee: The Bank of Nanjing Limited by Share Ltd. of Hangzhou city Small and micro businesses franchise branch Pledgor: ADLAI NORTYE BIOPHARMA Co.,Ltd. Registration number: 2017330000339 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201014 Granted publication date: 20170322 Pledgee: The Bank of Nanjing Limited by Share Ltd. of Hangzhou city Small and micro businesses franchise branch Pledgor: ADLAI NORTYE BIOPHARMA Co.,Ltd. Registration number: 2017330000339 |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170322 Termination date: 20211024 |